[R] – Remote Presentation Only

Poster Session (To be presented on November 18 from 7:00-9:00 p.m. CT)

P001 Frequency and covariates of chemoprevention use among women at high risk for breast cancer. Claire Conley. Georgetown University, Washington, D.C., USA.

P002 Timing onset of homologous recombination deficiency before cancer diagnosis in BRCA1/2 mutation carriers. Dominik Glodzik. Harvard Medical School, Boston, Massachusetts, USA.

P003 Computational Identification of Ovarian Cancer Candidate Genes with Mutated Protein Structures caused by Missense Variants. Ian Hou. The John Cooper School, The Woodlands, Texas, USA.

P004 Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer. Cassandra Moyer. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

P005 SLC38A5 characterization and its tumor promoting role in pancreatic ductal adenocarcinoma. Tyler Sniegowski. Texas Tech University Health Sciences Center, Lubbock, Texas, USA.


P007 Short-term PI3K inhibition prevents breast cancer in preclinical models. Amy Ku. Baylor College of Medicine, Houston, Texas, USA.

P008 Native Cell-Free DNA sequence analysis reliably infers epigenetically diverse subtypes of prostate cancer. Navonil Sarkar. Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

P009 Plasma concentrations of multiple oxysterols and risk of colorectal adenomas. Michael Passarelli. Dartmouth College, Hanover, New Hampshire, USA.

P010 Molecular mediators of the energy balance-colorectal cancer link: evaluating the gut microbiome and pro-inflammatory biomarkers. Caroline Himbert. Huntsman Cancer Institute, Salt Lake City, Utah, USA.


P012 Mutation hotspots in skin, bladder, and lung cancer as targets of carcinogenic risk assessment in clinically normal-appearing tissue. Sydney Grant. Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
P013 Impact of blood-based biomarkers for predicting lung cancer mortality in the PLCO cohort. Ehsan Irajizad. University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

P014 A novel role of mutant APC and n3-PUFA in reshaping cholesterol-dependent Wnt pathway-associated proteolipid nanocluster organization and signaling in colorectal cancer. Alfredo Erazo-Oliveras. Texas A&M University, College Station, Texas, USA.

P015 Mechanisms of mitochondrial dysfunction in development of mismatch repair-deficient endometrial cancer. Diana Moreno. Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, Texas, USA.

P016 Endomembranes accumulate unesterified cholesterol in Apc mutant models and humans with CRC as assessed by RNAseq and confocal microscopy. Monica Munoz Vega. Texas A&M University, College Station, Texas, USA.

P017 Early detection of ovarian cancer in high risk individuals using circulating miRNAs: The MiDe study. Kevin Elias. Brigham and Women’s Hospital, Boston, Massachusetts, USA.

P018 Differences in guideline-recommended age of human papillomavirus (HPV) vaccine initiation and completion in the United States. [R] Trinity Casimir. New York University, New York, New York, USA.

P019 Continued depression of breast and lung cancer screening among Medicare enrollees during the COVID-19 pandemic. Christopher Duc Doan. The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.

P020 Describing and modelling the burden of neoplasms in Ghana to guide cancer prevention and screening planning and allocation. Timothy Rebbeck. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

P021 Association of social determinants of health and healthcare-related factors with delayed total neoadjuvant therapy among rectal cancer patients from the National Cancer Database. Megan Mai. Texas Tech University Health Science Center, Lubbock, Texas, USA.


P023 The Impact of limited English proficiency and healthcare access on HPV vaccine uptake in the United States. [R] Marian Talip. North Carolina State University, Raleigh, North Carolina, USA.

P025 Tobacco Screening Practices and Perceived Barriers in Offering Tobacco Cessation Services in the Primary Prevention of Lung Cancer among Texas Healthcare Centers Providing Behavioral Health Treatment. Ammar Siddiqi. Rice University, Houston, Texas, USA.

P026 Exploring factors associated with preferences for human papillomavirus (HPV) self-sampling among racially- and ethnically-diverse women: A cross-sectional study. Serena Xiong. Washington University in St. Louis, St. Louis, Missouri, USA.

P027 Interest and uptake rates for cancer risk genetic testing in the AHEAD early detection program. Candace Westgate. Adventist Health, St. Helena, California, USA.


P029 Proteomic age acceleration associated with cancer risk in the Atherosclerosis Risk in Communities (ARIC) Study. Shuo Wang. University of Minnesota, Minneapolis, Minnesota, USA.

P030 Prospective analysis of plasma metabolites for early detection of high-grade serous ovarian cancer. Naoko Sasamoto. Brigham and Women’s Hospital, Boston, Massachusetts, USA.

P031 Glycerolipid metabolism is a key early-detection biomarker for spontaneous ovarian cancer onset. Kathryn Ellwood. University of Delaware, Newark, Delaware, USA.

P032 A novel multiplex immunoassay for the early detection of bladder cancer. Hideki Furuya. Cedars-Sinai Medical Center, Los Angeles, California, USA.


P034 Prevent Cancer-Greenville: Identifying and Influencing Cancer Risk. Larry Gluck. Prisma Health, Greenville, South Carolina, USA.

P035 Associations between Meat and Fish Intake and Aggressive Prostate Cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Jessica Sainyo. Arnold School of Public Health at The University of South Carolina, Columbia, South Carolina, USA.


P037 Association between circulating osteoprotegerin levels and estimated risk of BRCA1-associated breast cancer. [R] Sarah Park. University of Toronto, Women’s College Research Institute, Toronto, Ontario, Canada.
P038 Transcriptome-wide association study identifies novel genes associated with bladder cancer risk. Siting Li. Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA.

P039 Framework for genomic cancer risk assessment dissemination and implementation in Latin America: The GRACIAS (genetic risk assessment for cancer implementation and sustainment) study. Jeffrey Weitzel. Latin American School of Oncology, Sierra Madre, California, USA.

P040 Mutational Heterogeneity of Colorectal Cancers Across Ancestries and Its Implications for Cancer Early Detection. Preethi Sreenivasan. Natera, Inc., Austin, Texas, USA.

P041 Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers. Gustavo Cerqueira. Exact Sciences Corporation, Madison, Wisconsin, USA.

P042 A genomic model to predict cellular radiosensitivity. Benjamin Honan. University of Alabama at Birmingham, Birmingham, Alabama, USA.

P043 A precision medicine gap: limited recognition of colorectal patients eligible for germline testing in molecular residual disease testing setting. Jeffrey Weitzel. Natera, Inc., Austin, Texas, USA.

P044 A genetically engineered mouse Sertoli cell line survives chronic humoral immune factors when grafted into diabetic mice. Rachel Washburn. Texas Tech University Health Sciences Center, Lubbock, Texas, USA.

P045 T cells contribute to an inflammatory and immunosuppressive microenvironment in lung squamous cell carcinoma tumorigenesis. Táchira Pichardo. Boston University School of Medicine, Boston, Massachusetts, USA.

P046 CTLA4 targeted therapy using the lymphatic drug delivery system for treatment of metastatic lymph nodes. Radhika Mishra. Tohoku University, Sendai, Japan.

P047 A liposomal priming agent increases the sensitivity of liquid biopsies. Maria Martin Alonso. Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.


P049 A simplified, potentially point-of-care (POC), electrode method detects changes in the amount of cfDNA/ctDNA and evaluates the response of advanced cancer patients to therapy. Floyd Taub. aiGENE, Inc., Aurora, Colorado, USA.
P050 S100P- A promising novel biomarker with potential of early detection of gall bladder cancer. Neetu Rawal. All India Institute of Medical Sciences, New Delhi, India.

P051 The INSPIRE Study (Implementing Next-generation Sequencing for Precision Intervention and Risk Evaluation): Scaling Return of Genomic Results. Ilana Solomon. City of Hope, Duarte, California, USA.

P052 Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth. Ksenija Korac. The Texas Tech University Health Sciences Center, Lubbock, Texas, USA.

P053 Automatically constructed pedigrees accurately identify patients at risk for monogenic and polygenic forms of cancer. Scott Hebbring. Marshfield Clinic, Marshfield, Wisconsin, USA.


P055 Risk factors for second primary lung cancer among breast cancer survivors. Eunji Choi. Stanford University School of Medicine, Stanford, California, USA.


P057 Application of multi-cancer early detection to lung and breast cancer screening populations. Jennifer Dennison. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

P058 Rapid, noninvasive, office-based, esophageal cell collection for early detection of esophageal precancer and cancer. Suman Verma. Lucid Diagnostics Inc., Lake Forest, California, USA.


P061 Mechanisms by which Mito-LND inhibits KRAS mutant lung cancer. Katherine Weh. University of Michigan, Ann Arbor, Michigan, USA.

P063 Risk Factors Beyond Chemotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Lymphoma Survivors: A 15-Year SEER-Medicare Analysis. Abhay Singh. Cleveland Clinic, Cleveland, Ohio, USA.

P064 Breakpoint-agnostic translocation screening for childhood leukemia. Erin Marcotte. University of Minnesota, Minneapolis, Minnesota, USA.

P065 Effects of metformin on breast tissue inflammation in premenopausal women with components of metabolic syndrome. Liane Pinto. The University of Arizona, Tucson, Arizona, USA.

P066 Blood-based proteomic signatures associated with MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. Jody Vykoukal. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.


P068 A hybrid modelling approach for abstracting CT imaging indications by integrating natural language processing from radiology reports with structured data from electronic health records. Aparajita Khan. Stanford University School of Medicine, Stanford, California, USA.

P069 Screening under-served populations by mobile low dose computerized tomography (LDCT) scans results in stage shift with potential cures: Time for a change in health policy? Derek Raghavan. Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA.


P071 The role of unique mutations in colorectal carcinogenesis; Does race matter in precision medicine? Hassan Ashktorab. Howard University, Washington, D.C., USA.

P072 Direct demonstration of nano-electroporation using magnetoelectric nanoparticles in an ovarian cancer model based on propidium iodide uptake. Max Shotbolt. University of Miami, Miami, Florida, USA.

P073 Targeting JAK1 signaling for molecular prevention in clonal hematopoiesis. Pablo Sanchez Vela. Memorial Sloan Kettering Cancer Center, New York, New York, USA.

P074 Pregnancy and neonatal outcomes among early-onset colorectal cancer survivors: A nationwide case-control study. Stephanie Zhao. Washington University School of Medicine, St. Louis, Missouri, USA.

P075 Comparison of the tumor and lymph node immune microenvironment in early non-small cell lung cancer through multimodal single cell sequencing. Zhanhao Xi. Boston University School of Medicine, Boston, Massachusetts, USA.
P076 Contribution of the microbiome to a metabolomic signature predictive of risk for pancreatic cancer. Johannes Fahrmann. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

P077 A blood-based lipid biomarker panel for personalized risk assessment of breast cancer. Johannes Fahrmann. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

P078 Cancer cell derived extracellular vesicles convey protein signatures of small cell lung carcinoma. Jody Vykoukal. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.